Derin Ven Trombozu Gelişen Kanser Hastalarında Embolizm ve Kan Grupları Arasındaki İlişki.

Amaç: Venöz tromboembolizm (VTE) pulmoner embolizm ve/veya derin ven trombozundan oluşan önemli bir morbidite ve mortalite sebebidir. VTE için birçok risk faktörü araştırılma konusu olmuştur ve halen araştırılmaktadır. Kan grubu antijenleri de bu konulardan biridir.Metod: Bülent Ecevit Üniversitesi Tıp Fakültesi Onkoloji kliniğinde 2004-2012 yılları arasında tedavi alan ve takipleri yapılan hasta dosyaları retrospektif olarak incelendi.Bulgular: Her iki grup arasında yaş, cinsiyet ve laboratuar özellikleri arasında istatiksel olarak anlamlı fark saptanmadı. En çok görülen kanser türleri kolorektal, jinekolojik maligniteler ve meme kanseriydi. A kan grubu DVT grubunda %52 oranında saptanmış olup kontrol grubu ile anlamlı fark izlenmedi (OR 1.3, CI %95, P 0.37). 0 kan grubu olanlarda DVT daha az saptanmakla birlikte istatiksel anlam yoktu (OR 0.6 CI%95, P 0.2). Sonuç olarak bizim hasta grubumuzda kan grubunun DVT gelişimi için ek bir risk faktörü katmadığı ortaya konulmuş olup diğer çalışmalardakinden faklı olması da bizim hasta grubunun sadece kanser hastalarından oluşmasına bağlı olabilirdi. Ayrıca kanser hastalarında birçok faktöre bağlı olarak tromboz eğiliminde artış olabilmektedir.

Relationship Between The Embolism and Blood Group in Cancer Patients with Deep Vein Thrombosis

Background: Venous thromboembolism (VTE) including the pulmonary embolism and / or deep vein thrombosis is an important cause of morbidity and mortality. Many risk factors had been investigated for VTE and still under investigation. Blood group antigen is one of these factor.Methods: Patients who followed and treated between 2004-2012 in the oncology clinic of Bülent Ecevit University School of Medicine were retrospectively studied.Results: There was no statistically significant difference between the two groups for age, gender and laboratory parameters. The most common type of cancers were colorectal, gynecological and breast cancer. We detected 52% of blood group A in the DVT group and there was no significant difference with the control group (OR 1.3, CI 95%, P 0.37). 0 blood group had detected fewer than control but there was no statistical significance between the groups (OR 0.6 CI 95%, P 0.2).In conclusion, our study showed that, ABO blood group did not have an additional risk factor for the development of DVT in cancer patients. The difference from the other studies is our stud population had only cancer patients. Also, many factors can increase tendency to thrombosis in cancer patients due to cancer.

___

  • Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest. 2009 Oct;136(4):983-90.
  • Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997 Nov;78(5):1316-8.
  • Mıller JR, Baggenstoss AH, Comfort MW. Carcinoma of the pancreas; effect of histological types and grade of malignancy on its behavior. Cancer. 1951 Mar;4(2):233-41.
  • Robinson WM, Roisenberg I. Venous thromboembolism and ABO blood groups in a Brazilian population. Hum Genet 1980;55:129– 131.
  • Wautrecht JC, Galle C, Motte S, Dereume JP, Dramaix M. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998;79:688–689.
  • Wiggins KL, Smith NL, Glazer NL, Rosendaal FR, Heckbert SR, Psaty BM et al. ABO genotype and risk of thrombotic events and hemorrhagic stroke. J Thromb Haemost. 2009 Feb;7(2):263-9.
  • Allan TM, Dawson AA. ABO blood groups and ischaemic heart disease in men. Br Heart J. 1968 May;30(3):377-82.
  • Kurtoğlu MH, Sivrikoz E. Derin Ven Trombozu: Tanı, Tedavi, Proflaksi. Harran Üniversitesi Tıp Fakültesi Dergisi 2008;5(1):34- 42.
  • Tirado I, Mateo J, Soria JM, Oliver A, Martínez-Sánchez E, Vallvé C et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 2005 Mar;93(3):468-74.
  • Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost. 2005 Jan;3(1):183- 5.
  • Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost. 2007 Apr;97(4):534-41.
  • Wolpin BM, Kabrhel C, Varraso R, Kraft P, Rimm EB, Goldhaber SZ et al. Prospective study of ABO blood type and the risk of pulmonary embolism in two large cohort studies. Thromb Haemost. 2010 Nov;104(5):962-71.
  • Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, Rafferty I et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 2008 May 9;4(5).
  • Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE et al. , Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1958-67.
  • Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010 May 1;19(9):1863-72. Epub 2010 Feb 18.